---
title: "Assembly Biosciences (ASMB) Gets a Buy from Guggenheim"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281778844.md"
description: "Guggenheim's Vamil Divan has reiterated a Buy rating on Assembly Biosciences (ASMB) with a price target of $43.00. Divan, a 5-star analyst, has an average return of 9.8% and a 56.28% success rate. Assembly Biosciences also received a Buy from H.C. Wainwright's Patrick Trucchio, while TipRanks – xAI issued a Sell rating on April 1."
datetime: "2026-04-06T16:05:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281778844.md)
  - [en](https://longbridge.com/en/news/281778844.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281778844.md)
---

# Assembly Biosciences (ASMB) Gets a Buy from Guggenheim

In a report released on April 2, Vamil Divan from Guggenheim reiterated a Buy rating on Assembly Biosciences, with a price target of $43.00.

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Divan is a 5-star analyst with an average return of 9.8% and a 56.28% success rate. Divan covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals, Savara, and Pfizer.

In addition to Guggenheim, Assembly Biosciences also received a Buy from H.C. Wainwright’s Patrick Trucchio in a report issued on March 26. However, on April 1, TipRanks – xAI reiterated a Sell rating on Assembly Biosciences (NASDAQ: ASMB).

### Related Stocks

- [ASMB.US](https://longbridge.com/en/quote/ASMB.US.md)

## Related News & Research

- [Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference](https://longbridge.com/en/news/286404799.md)
- [Analyst Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target Amid Pipeline Progress and 2028 Cash Runway](https://longbridge.com/en/news/286291566.md)
- [xAI burned $6.4B last year. SpaceX’s IPO filing shows why the spending is far from over](https://longbridge.com/en/news/287126781.md)
- [SpaceX reveals soaring losses ahead of record IPO bid](https://longbridge.com/en/news/287133561.md)
- [In SpaceX’s IPO, Elon Musk is a risk factor](https://longbridge.com/en/news/287153110.md)